Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 154 of 5804
-
New antibody combo aims to outsmart Hard-to-Treat lymphoma
Disease control Recruiting nowThis study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Sharper eye for prostate cancer: new imaging agent aims to spot hidden spread
Diagnosis Recruiting nowThe aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Phase: PHASE3 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Could a daily pill help restore skin color in vitiligo?
Disease control OngoingVitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo (NSV). Adverse effects and change in d…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Targeted Antibody-Drug combo aims to tackle High-Risk bladder cancer
Disease control OngoingThis is a prospective, open, single-center clinical study of the anti-HER2(Human epidermal growth factor receptor-2) ADC(antibody-drug conjugate) drug Disitamab Vedotin in combination with BCG(bacillus Calmette-Guerin) therapy in very high-risk NMIBC(Non-muscle invasive bladder c…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Blood test catches cancer early: new drug aims to stop spread
Disease control Recruiting nowThis is an international, multi-center, randomised, open label, superiority phase III trial of elacestrant vs standard endocrine therapy in patients with ER+/HER2- breast cancer and ctDNA relapse. During the ctDNA screening phase, patients will be tested at different timepoints …
Phase: PHASE3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could 5 radiation doses replace 45 for prostate cancer?
Disease control Recruiting nowThis phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipm…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill nemtabrutinib takes on standard blood cancer drugs in major trial
Disease control Recruiting nowThe goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New MS drug frexalimab faces off against standard treatment in major trial
Disease control OngoingThe purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug cocktail aims to put mantle cell lymphoma into deep remission
Disease control OngoingTrAVeRse is a multicentre, open-label, Phase II study of AVR in treatment naïve MCL participants. The primary objective will be to assess the rate of MRD-negative CR at end of induction after completing 13 cycles of AVR. Participants achieving an MRD-negative CR at the end of AVR…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for tough prostate cancer: immunotherapy meets targeted radiation
Disease control OngoingIn this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.
Phase: PHASE1, PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New pill could outshine standard shot for tough breast cancer
Disease control Recruiting nowThis is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants w…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
AI takes on cancer radiotherapy: can a computer plan treatment in minutes?
Knowledge-focused OngoingThe aim of this study is to look at whether an Artificial Intelligence (AI) based computer program can automate two components of the radiotherapy treatment pathway to a sufficient quality standard to enable its routine clinical use. The two components include the delineation (ou…
Sponsor: University College, London • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
New hope for endometrial cancer: targeted drug takes on chemo in major trial
Disease control OngoingResearchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical s…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo therapy targets Hard-to-Treat stomach cancers in Mid-Stage trial
Disease control OngoingThis phase II trial compares atezolizumab in combination with chemotherapy (docetaxel, oxaliplatin, leucovorin calcium, fluorouracil, capecitabine) to atezolizumab alone for controlling the growth and/or spreading of the disease in patients with gastric or gastroesophageal juncti…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Smarter radiation for head & neck cancer: Biopsy-Guided treatment may spare patients from dry mouth
Disease control Recruiting nowRationale \| Elective neck irradiation is performed in head and neck cancer patients treated with definitive (chemo)radiotherapy. The aim is to eradicate nodal metastases that are not detectable by pretreatment imaging techniques. It is conceivable that personalized neck irradiat…
Phase: PHASE3 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New vaccine could stop recurring yeast infections in their tracks
⭐️ VACCINE ⭐️ OngoingIn this study, the pentavalent bioconjugate candidate vaccine (Candi5V) against Candida will be tested to obtain first-time-in-human (FTIH) data on its safety, immunogenicity, and preliminary efficacy in women with recurrent vulvovaginal candidiasis.
Phase: PHASE1, PHASE2 • Sponsor: LimmaTech Biologics AG • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:10 UTC
-
New hope for late-stage breast cancer patients with no other options
Disease control Recruiting nowThis is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (a…
Phase: PHASE3 • Sponsor: BriaCell Therapeutics Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug cocktail aims to stop smoldering myeloma in its tracks
Disease control Recruiting nowThe purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.
Phase: PHASE2 • Sponsor: Carl Ola Landgren, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Immunotherapy duo takes aim at tough pancreatic cancer before surgery
Disease control Recruiting nowThis is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug trial aims to shrink painful lymphatic growths in kids and adults
Disease control Recruiting nowThe main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo.
Phase: PHASE2, PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC